Answers are grounded in this paper and cite their sources.
Background and objectives Prior studies show that a small proportion of patients reach the recommended 3 years of treatment in allergen immunotherapy. Recently, a connected device (iPUMP®) was developed to enhance patient engagement and optimize treatment management of sublingual immunotherapy. The SPEED study evaluated the impact of the iPUMP on treatment adherence and persistence and examined the long-term use of sublingual immunotherapy in real-life. Methods The observational SPEED study consisted of two parts: a retrospective analysis to evaluate persistence, which tracked the renewal of sublingual immunotherapy using 22,250 orders (representing 10,567 treatments) from the Stallergenes Greer database; and a prospective survey conducted from May 29 to November 29, 2024, recruiting 381 patients starting sublingual immunotherapy for cat or house dust mites allergy. Patients were grouped into an iPUMP cohort ( n = 181) and a standard care cohort ( n = 200). Questionnaire data were collected after 3 months of treatment. Descriptive statistics were used for analysis of both components of the study. Results Eighty-two percent of patients using the iPUMP® renewed their sublingual immunotherapy, compared to 67 % of those who did not. The use of the iPUMP® consistently increased daily intake (consumption volumes) across all age groups. The connected device notably facilitated independence in younger patients. In the iPUMP® group, parental assistance decreased from 50 % at initiation to 29 % after 3 months, while in the standard care group, parental assistance increased in the same period (from 24 % to 58 %). Most parents (50 %) felt perfectly reassured about sublingual immunotherapy delivery when using the iPUMP®, compared to 36 % without the device. At treatment initiation, over 70 % of users reported reassurance regarding proper dose delivery, timing, and pressure control. As a treatment support, eight out of ten users found the iPUMP® helpful. A majority of both younger (80 % of 5 to 12-year-olds) and older (79 % of those over 12) patients believed the iPUMP® was an aid and plan to use it. Conclusions The study suggests a substantial impact of the iPUMP® on treatment renewal rates and treatment adherence, especially in younger patients. Consequently, it could be an effective tool to improve adherence to sublingual immunotherapy by facilitating an autonomous approach and strengthening parents' confidence.
No takes yet. Share an insight, caveat, or question.
Cottet et al. (2026) studied this question.